









# Pathological Report



Foamy macrophages



Lymphocytes and plasma cells




fibrosis


# Pathological Report




Mahidol University  
Faculty of Medicine Ramathibodi Hospital




CD3




CD20




CD138



IgG



IgG4



CD68



# Pathological Report



## **Pituitary tissue biopsy**

- Chronic hypophysitis with clusters of foamy macrophages
- Negative for malignancy or pituitary tissue
- IHC reveals
  - CD3 : positive in small lymphocytes
  - CD20 : positive in small lymphocytes
  - CD138 : positive in few plasma cells
  - CD68 : positive in multiple or cluster of foamy macrophages
  - IgG : positive in few plasma cells
  - IgG4 : negative

From histomorphology and IHC panel,  
**xanthomatous hypophysitis** is most likely




# Diagnosis : Xanthomatous hypophysitis

# Hypophysitis






Primary (autoimmune or idiopathic)
Lymphocytic hypophysitis
Granulomatous hypophysitis
Xanthomatous hypophysitis
IgG-4 mediated (plasmacytic) hypophysitis
Necrotizing hypophysitis
Mixed forms (lymphogranulomatous; xanthogranulomatous)

Secondary	
AIH associated with other endocrinopathies	Autoimmune Polyglandular Syndrome, Autoimmune thyroid disease, Autoimmune adrenalitis, Type 1 diabetes mellitus
AIH associated with systemic diseases	Erdheim-Chester disease, Rheumatologic conditions (e.g.: sarcoidosis, Sjogren's, SLE), Vasculitides, Primary biliary cirrhosis, Atrophic gastritis, Optic neuritis, Myocarditis, IgG4-related disease, Langerhans cell histiocytosis, Rosai-Dorfman disease, Tolosa-Hunt syndrome, Cogan's syndrome, Thymoma (anti-Pit-1 antibody syndrome)
AIH secondary to Drugs	Immune checkpoint inhibitors, Interferon- $\alpha$ , Ribavirin, Ustekinumab
AIH secondary to sellar and/or suprasellar lesions	Germinoma, Rathke's cleft cyst, Craniopharyngioma, Pituitary adenoma, Pituitary apoplexy, Pituitary hyperplasia, Primary pituitary lymphoma, Gliomas, Meningiomas, Pituitary cytomas, Chordomas, Teratomas, Dermoids, Epidermoids
AIH secondary to infections	Tuberculosis, Syphilis, Viruses, Parasites, Abscesses









# Summary of hypophysitis types, features and treatment options

Hypophysitis type	Etiology, demographics	Clinical presentation	Treatment, outcome
<p>Lymphocytic</p>  <p>Lymphocytic infiltration, plasma cells, histiocytes and fibrosis</p>	<p>Primary: F &gt; M; F: 3<sup>rd</sup> decade, pregnancy and peripartum; M: 4<sup>th</sup> decade; co-existing autoimmunity</p> <p>Secondary: Found in sellar and suprasellar lesions (adenoma, craniopharyngioma, cyst, germinoma, lymphoma, etc.)</p>	<p>Deficiencies: Anterior hypopituitarism; DI is less frequent</p> <p>MRI: Enlarged homogeneously enhancing gland; stalk thickening. Empty sella in later stages</p> <p>Autoimmunity: thyroid disease, type 1 DM, celiac disease, connective tissue disorders, autoimmune GI disorders</p>	<p>Observation in mild-moderate cases</p> <p>GC in moderate-severe cases</p> <p>Immunosuppressants, surgery, radiation in GC-resistant cases</p> <p>Outcome is usually favorable</p>
<p>Granulomatous</p>  <p>Multinucleated giant cells, histiocytes, lymphocytes, granulomas</p>	<p>Primary: Idiopathic F &gt; M, 5<sup>th</sup> decade</p> <p>Secondary: Isolated or part of systemic disease, e.g. sarcoidosis, GPA, tuberculosis, LCH/ECD</p>	<p>Deficiencies: Anterior hypopituitarism, frequent DI.</p> <p>More severe than lymphocytic type, frequent headache</p> <p>MRI: Enlarged gland; stalk thickening</p>	<p>GC less effective for idiopathic granulomatous hypophysitis</p> <p>Immunosuppressants, surgery, radiation for GC-resistant, LCH</p> <p>Chemotherapy (LCH, ECD)</p> <p>Outcome variable</p>
<p>Xanthomatous</p>  <p>CD68 positive foamy macrophages, cholesterol clefts, hemosiderin deposits</p>	<p>F &gt; M, 4<sup>th</sup> decade</p> <p>Secondary to local processes; hemorrhage/rupture of Rathke cleft cyst, craniopharyngioma; also seen in systemic autoimmune disorders</p>	<p>Deficiencies: Anterior hypopituitarism, DI</p> <p>Frequent headache</p> <p>MRI: Cystic mass</p>	<p>Surgery is usually necessary</p> <p>Limited response to GC</p> <p>Outcome variable; complete recovery has been described</p>





# Summary of hypophysitis types, features and treatment options

<p><b>Necrotizing</b></p>  <p>Extensive necrosis, lymphocytes, plasmacytes, few eosinophils</p>	<p>Very rare, few cases described F &gt; M, 2<sup>nd</sup>–4<sup>th</sup> decade</p> <p>Etiology unknown; possibly autoimmune</p>	<p>Deficiencies: Anterior hypopituitarism, DI</p> <p>MRI: Enlarged gland; stalk thickening; poor contrast enhancement; apoplexy-like appearance</p>	<p>Surgery for mass effect</p> <p>Role of GC and immunosuppressants unknown</p> <p>Pituitary deficiencies usually persist</p>
<p><b>IgG4-related</b></p>  <p>≥10 HPF IgG4-positive plasma cells, storiform fibrosis</p>	<p>M &gt; F, 5<sup>th</sup>–7<sup>th</sup> decade</p> <p>Secondary to IgG4 related disease but can be isolated</p>	<p>Deficiencies: Anterior hypopituitarism; DI very common</p> <p>MRI: Enlarged gland; stalk thickening</p> <p>Systemic IgG4 disease: retroperitoneal fibrosis, pancreatitis, sialadenitis, polyadenopathy, Riedel thyroiditis; IgG4 levels variable</p>	<p>GC – usually excellent radiographic response to supraphysiologic doses</p> <p>Hypopituitarism may be permanent</p>
<p><b>Immunotherapy induced</b></p>  <p>Diffuse infiltration with lymphocytes (left) and macrophages (right)</p>	<p>M &gt; F, 6<sup>th</sup> decade</p> <p>Ipilimumab: 8–10% (up to 17%) Tremelimumab: 0–2.6% Nivolumab: 0–3% Pembrolizumab: 0–5% Nivolumab + Ipilimumab: 8–13%</p>	<p>Deficiencies: Anterior hypopituitarism with predominant AI; rarely DI</p> <p>MRI: Enlarged gland (usually mild/moderate); stalk thickening</p>	<p>Replacement dose GC in mild-moderate cases</p> <p>High-dose GC and withdraw immunotherapy temporarily in severe cases</p> <p>Radiographic outcome favorable; pituitary deficiencies usually persistent</p>
<p><b>Other autoimmune</b></p>  <p>Pathology not well described; lymphocytic infiltration</p>	<p>Anti-PIT-1 hypophysitis – associated with thymoma</p> <p>Anti-POMC or anti-ACTH – associated with APS, ectopic POMC and ACTH expressing NETs</p> <p>Antibodies against pituitary cells have been implicated</p>	<p>Deficiencies: Anti-PIT-1 hypophysitis – GH, PRL, and TSH deficiency</p> <p>Anti-POMC or Anti-ACTH: Isolated ACTH deficiency</p> <p>Other isolated deficiencies</p> <p>MRI: usually normal or atrophic gland</p>	<p>Role of GC is unknown</p> <p>Treat underlying condition</p> <p>Pituitary deficiencies persist</p>



# Xanthomatous hypophysitis

- The rarest subtype of primary hypophysitis
- Only 37 cases from 1998-2022


## Characteristic

**Age** : mean 39.1 years (range 12-72 years)

**Gender** : 75% were female

## Symptoms

- Headache 68.6%
- Visual impairment 34.3%
- DI 36.1%
- Menstrual disorder in female 66.7%
- Fever 8.3%





# Xanthomatous hypophysitis

## Pituitary hormone dysfunction

- Hypogonadotropic hypogonadism 63.6%
- Adrenocortical insufficiency 54.5%
- Central hypothyroidism 54.6%
- GH deficiency 63.6%
- Hyperprolactinemia 42.4%

## MRI presentation


- Cystic mass with ring or peripheral enhancement
- Mean maximum diameter was  $16.3 \pm 4.8$  mm.
- Pituitary stalk thickening : 50.0%

**Gross presentation** : cystic lesion with yellowish pus-like fluid

**Pathological feature** : foamy histiocyte infiltration, which can be marked by **CD68** glycoprotein on immunohistochemistry

B


Prevalence (%)	36.1	42.4	63.6	36.4	54.6	54.6
n/N	13/36	14/33	21/33	12/33	18/33	18/33



# Xanthomatous hypophysitis

## Treatment

- Lack of best evidence for treatment  
-- lack of follow up data
- Surgical resection should be considered, especially for patients suffering from mass effects and pituitary dysfunction  
→ total mass resection is recommended
- Close follow-up and routine assessment of pituitary function
- Hormone replacement therapy





# Summary

- Xanthomatous hypophysitis is a rare entity of primary hypophysitis. Less than 40 cases have been reported until now.
- Patients could present with both anterior and posterior pituitary hormone dysfunction.
- Not all hypophysitis patients have stalk thickening
- Pituitary biopsy is usually considered either when a diagnosis is unclear.
- The pathological results show a presence of foamy macrophages and positive CD68
- There is no therapeutic cure. The main management is hormone replacement.